Skip to main content

Medical Policy Implementation: Triamcinolone Acetonide Extended-Release (Zilretta)

Effective February 1, 2019, Horizon Blue Cross Blue Shield of New Jersey will change the way we process certain claims based on the guidelines of our medical policy, Triamcinolone Acetonide Extended-Release (Zilretta).

We encourage you to review this policy content in our Medical Policy Manual.


Based on the guidelines of our medical policy, Triamcinolone Acetonide Extended-Release (Zilretta):

  • Medical record information may be requested to help us determine the medical appropriateness of CPT® code Q9993 included on claims for services provided on and after February 1, 2019.

    Following our review of medical record information, CPT code Q9993 may be denied as an experimental/investigative, non-covered services

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims on and after February 1, 2019.

CPT® is a registered mark of the American Medical Association.

Published on: November 1, 2018, 12:25 PM ET
Last updated on: November 1, 2018, 14:11 PM ET